- Revamped AlloMune System Development Strategy: The company revised its clinical development strategy for the AlloMune System and will now employ kits consisting of BioTransplant's proprietary antibody MEDI-507, also known as siplizumab, in combination with products that have already been approved in the United States.
The company also announced that the restructuring would not affect its agreement with MedImmune or MedImmune's development efforts for MEDI-507.
BioTransplant says it is targeting the use of the Eligix Cell Separation products as a component of the AlloMune System, which, along with its proprietary monoclonal antibody MEDI-507
, is being developed as a complete approach to increase the safety and efficacy of immune modulation and transplantation for cancer and other life threatening diseases.
Food and Drug Administration (FDA) for its MEDI-507 antibody, when used as one of the key components of the AlloMune transplantation system.
BioTransplant says MEDI-507 is a humanized monoclonal antibody that binds specifically to the CD2 antigen receptor found on T cells and natural killer (NK) cells.